2023-05-09 08:48:50 ET
- ESSA Pharma press release ( NASDAQ: EPIX ): Q2 GAAP EPS of -$0.16 beats by $0.04 .
- ESSA recorded a comprehensive loss of $7.1 million for the first quarter ended March 31, 2023,
- At March 31, 2023, the Company had available cash reserves and short-term investments of $157 million reflecting the gross proceeds of the February 2021 financing of approximately $150.0 million and July 2020 financing of $48.9 million, less operating expenses in the intervening period. The Company's cash position is expected to be sufficient to fund current and planned operations through 2025.
For further details see:
ESSA Pharma GAAP EPS of -$0.16 beats by $0.04